2005 - Myriad Genetics' Follow-on Study of Flurizan Demonstrates Cognitive Improvement in Alzheimer's Disease
Flurizan Reverses Disease Course and Improves Cognitive Function in Follow-on
SALT LAKE CITY, Nov. 15 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc.(Nasdaq: MYGN) (http://www.myriad.com) announced today that an analysis of data from its Phase 2 follow-on study of Flurizan(TM) in patients with mild Alzheimer's disease showed that study participants improved as a group, regaining cognitive ability from months 12 through 18.
Results of the 6-month follow-on study were presented today at the Neuroscience 2005 meeting in Washington, D.C., by Sandra E. Black, M.D., Professor of Neurology at the University of Toronto and lead investigator in Canada for the Phase 2 trial of Flurizan in patients with Alzheimer's disease.
The Phase 2 trial of Flurizan monitored patients with Alzheimer's disease for a period of 12 months. At the end of the 12-month period, the group of mild patients taking 800 mg twice daily showed an average decline from their baseline score at enrollment of 2.64 points on the Alzheimer's Disease
Assessment Scale -- Cognitive Function Subscale (ADAS-cog).
In contrast, the placebo group experienced a 3.78 point decline over the same 12 months. In the follow-on to the Phase 2, patients on Flurizan for three additional months
regained 0.38 points to 2.27, an improvement of 14 percent, and by 18 months the average ADAS-cog score had further improved to 1.78 points, a total gain in cognition of 0.86 points.
These data demonstrate an increase in cognition
upon continued treatment that amounted to a 33% improvement over the follow-on period.
"The 18-month follow-on data are striking in that Flurizan-treated patients appear to be regaining cognitive functions like memory and thinking ability that they had previously lost to the disease," said Daniel Christensen, M.D., Clinical Professor of Neurology, Psychiatry and Pharmacology at the University of Utah.
MORE
Message 21885816
Comment:
I don't know if the above cognitive function *increase*
is real or just a fluke. But if it is real then I think
it fair to ask the question:
How would this drug be for Mild Cognitive Impairment?
IOW - cut down the AD sucker before it builds up traction
and begins to take over. |
